Comparative effects of nonsedating histamine H1 receptor antagonists, ebastine and terfenadine, on human Kv1.5 channels

European Journal of Pharmacology

Volumn 326, Issue 2-3, 1997, Pages 257-263

  Valenzuela, Carmen ^a   Delpón, Eva ^a   Franqueza, Laura ^a   Gay, Pilar ^a   Vicente, Javier ^a   Tamargo, Juan ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Antihistaminic agent; Carebastine; Ebastine; hKv1.5 channel; K+ current; Terfenadine

Indexed keywords

CAREBASTINE; DRUG METABOLITE; EBASTINE; HISTAMINE H1 RECEPTOR ANTAGONIST; POTASSIUM CHANNEL; TERFENADINE; TERFENADINE CARBOXYLATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE TRANSFER; HUMAN; IN VITRO STUDY; MOUSE; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL;

EID: 0030974081     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)85421-0     Document Type: Article

References (42)

1. Berul C., Morad M. Regulation of potassium channels by nonsedating antihistamines. Circulation. 91:1995;2220-2225.
2. + current in adult rat atrial myocytes. Am. J. Physiol. 260:1991;H1236-H1247.
3. Chen Y., Woosley R. Electrophysiological actions of astemizole. Clin. Pharmacol. Ther. 55:1994;146.
4. Colatsky T., Follmer C., Starmer C. Channel specificity in antiarrhythmic drug action. Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation. 82:1990;2235-2242.
5. Crumb W., Wible B., Arnold A., Payne J., Brown A. Blockade of multiple human cardiac potassium currents by the antihistamine terfenadine: possible mechanism for terfenadine-associated cardiotoxicity. Mol. Pharmacol. 47:1995;181-190.
6. Davies A., Harindra V., McEwan A., Ghose R. Cardiotoxic effect with convulsions in terfenadine overdose. Br. Med. J. 298:1989;325.
7. Deal K., England S., Tamkun M. Molecular physiology of cardiac potassium channels. Physiol. Rev. 76:1996;49-67.
8. Delpón E., Valenzuela C., Pérez O., Franqueza L., Gay P., Snyders D., Tamargo J. Mechanisms of block of a human cloned potassium channel by the enantiomers of a new bradycardic agent: S-16257-2 and S-16260-2. Br. J. Pharmacol. 117:1996;1293-1301.
9. 1-receptor antagonist therapy. Clin. Pharmacokinet. 21:1991;372-393.
10. Garteiz D., Hook R., Walker B., Okerholm R. Pharmacokinetics and biotransformation studies of terfenadine in man. Arzneim.-Forsch. 32:1982;1185-1190.
11. Hamill O., Marty A., Neher E., Sackmann B., Sigworth F. Improved patch-clamp techniques for high resolution current recording from cells and cell-free membrane patches. Pflüg. Arch. 391:1981;85-100.
12. Hondeghem L., Snyders D. Class III antiarrhythmic agents have a lot of potential, but a long way to go: reduced effectiveness and dangers of reverse use-dependence. Circulation. 81:1990;686-690.
13. Investigator's Brochure, 1995. Rôhne-Poulenc Rorer, Collegeville. Data on file.
14. Jeck C., Boyden P. Age-related appearance of outward currents may contribute to developmental differences in ventricular repolarization. Circ. Res. 71:1992;1390-1403.
15. + currents in nonfailing human hearts: similarities between right septal subendocardial and left subepicardial ventricular myocytes. Circulation. 92:1995;1179-1187.
16. Leeson G., Chan K., Knapp W., Biedenbach S., Wright G., Okerholm R. Metabolic disposition of terfenadine in laboratory animals. Arzneim.-Forsch. 32:1982;1173-1178.
17. + current in human ventricular myocytes. Circ. Res. 78:1996;689-696.
18. 1-receptor antagonist ebastine and its metabolite carebastine in rats, guinea pigs, dogs and monkeys. Arzneim.-Forsch. 44:1994;55-59.
19. + channel protein in explanted cardiac tissue. J. Clin. Invest. 96:1995;282-292.
20. Monahan B., Ferguson C., Killeavy E., Lloyd B., Troy J., Cantilena L. Torsades de pointes occurring in association with terfenadine use. J. Am. Med. Assoc. 264:1990;2788-2790.
21. + channel cloned from human heart. Mol. Pharmacol. 44:1993;1240-1245.
22. Roberds S.L., Knoth K.M., Po S., Blair T.A., Bennett P.B., Hartshorne R.P., Snyders D.J., Tamkun M.M. Molecular biology of the voltaged-gated potassium channels of the cardiovascular system. J. Cardiovasc. Electrophysiol. 4:1993;68.
23. Roden D. Current status of class III antiarrhythmic drug therapy. Am. J. Cardiol. 72:1993;44B-49B.
24. Roy M.-L., Dumaine R., Brown A. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation. 94:1996;817-823.
25. 1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and prylamine. Circ. Res. 76:1995;110-119.
26. Snyders D., Yeola S. Determinants of antiarrhythmic drug action. Electrostatic and hydrophobic components of block of the human cardiac hKv1.5 channel. Circ. Res. 77:1995;575-583.
27. Snyders D., Knoth K., Roberds S., Tamkun M. Time-, state- and voltage-dependent block by quinidine of a cloned human cardiac channel. Mol. Pharmacol. 41:1992;332-339.
28. Snyders D., Tamkun M., Bennett P. A rapidly activating and slowly inactivating potassium channel cloned from human heart. J. Gen. Physiol. 101:1993;513-543.
29. Spatzenegger M., Jaegger W. Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab. Rev. 25:1995;397-417.
30. + channel cDNAs from human ventricle. FASEB J. 5:1991;331-337.
31. + current activation in guinea pig ventricular myocytes. Circ. Res. 74:1994;687-699.
32. Valenzuela C., Delpón E., Tamkun M., Tamargo J., Snyders D. Stereoselective block of a human cardiac potassium channel (Kv1.5) by bupivacaine enantiomers. Biophys. J. 69:1995;418-427.
33. Valenzuela C., Delpón E., Franqueza L., Gay P., Snyders D., Tamargo J. Comparative effects of nonsedating histamine H1-receptor antagonist on human Kv1.5 channels. Br. J. Pharmacol. 118:1996;105P.
34. Valenzuela C., Delpón E., Franqueza L., Gay P., Pérez O., Tamargo J., Snyders D. Class III antiarrhythmic effects of zatebradine: time-, state-, use- and voltage-dependent block of hKv1.5 channels. Circulation. 94:1996;562-570.
35. Vincent J., Liminana R., Meredith P., Reid J. The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects. Br. J. Clin. Pharmacol. 26:1988;497-501.
36. + current similar to Kv1.5 cloned channel currents. Circ. Res. 73:1993;1061-1076.
37. + channels: ionic and gating current studies. J. Gen. Physiol. 85:1985;539-554.
38. Wiseman L., Faulds D. Ebastine: a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Drugs. 51:1996;260-277.
39. Woodhull A. Ionic blockade of sodium channels in nerve. J. Gen. Physiol. 61:1973;687-708.
40. Woosley R., Chen Y., Freiman J., Gillis R. Mechanism of the cardiotoxic actions of terfenadine. J. Am. Med. Assoc. 269:1993;1532-1536.
41. 1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects. Arzneim.-Forsch. 44:1994;59-64.
42. Yang T., Prakash C., Roden D., Snyders D. Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers. Br. J. Pharmacol. 115:1995;267-274.